Standard BioTools Inc.
LAB
$1.29
-$0.04-3.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.82% | 30.65% | 28.70% | 12.39% | -6.64% |
| Total Other Revenue | -- | -- | -6.02% | 156.55% | 10.17% |
| Total Revenue | 36.82% | 30.65% | 27.73% | 11.53% | -7.35% |
| Cost of Revenue | 29.04% | 13.17% | 11.49% | 92.26% | 26.55% |
| Gross Profit | 45.60% | 55.02% | 50.57% | -21.95% | -28.85% |
| SG&A Expenses | 36.87% | 36.71% | 40.81% | 23.86% | 4.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.76% | 35.12% | 38.50% | 24.30% | 2.69% |
| Operating Income | -32.16% | -41.63% | -56.67% | -47.99% | -19.02% |
| Income Before Tax | -23.99% | -48.16% | -37.88% | -17.87% | 1.96% |
| Income Tax Expenses | -945.00% | 2.65% | 19.91% | -84.21% | 150.63% |
| Earnings from Continuing Operations | -23.52% | -47.98% | -37.78% | -16.95% | 1.82% |
| Earnings from Discontinued Operations | 48.79% | -45.60% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.56% | -47.56% | -86.03% | -64.53% | -40.99% |
| EBIT | -32.16% | -41.63% | -56.67% | -47.99% | -19.02% |
| EBITDA | -54.40% | -58.74% | -64.74% | -43.56% | 12.11% |
| EPS Basic | 64.50% | 64.34% | 41.45% | 25.93% | 15.31% |
| Normalized Basic EPS | 51.90% | 61.94% | 67.68% | 52.32% | 39.07% |
| EPS Diluted | 64.87% | 64.68% | 42.04% | 25.77% | 14.40% |
| Normalized Diluted EPS | 51.90% | 61.94% | 67.68% | 52.32% | 39.07% |
| Average Basic Shares Outstanding | 82.33% | 181.50% | 346.12% | 253.34% | 161.12% |
| Average Diluted Shares Outstanding | 82.33% | 181.50% | 346.12% | 253.34% | 161.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |